Investigational antipsychotic offers new MOA

A treatment with a new mechanism of action for treating schizophrenia may be on the horizon. A phase II investigational agent that targets metabotropic glutamate 2/3 (mGlu2/3) receptors has demonstrated antipsychotic activity. LY2140023, from Eli Lilly, has shown promising results in a clinical trial where patients were assigned to four weeks of treatment with either LY2140023, olanzapine (Zyprexa, Lilly), or placebo. Both the investigational agent and olanzapine showed a statistically significant improvement versus placebo on the Positive and Negative Syndrome Scale (PANSS), a scale commonly used to evaluate symptoms of schizophrenia. According to researchers, the findings provide evidence that the mGlu2/3 receptor agonists have antipsychotic properties and could lead to a new therapeutic approach to treating neuropsychiatric disorders. The study was published in the journal Nature Medicine.

Click here to see more articles from Drug Topics Daily News.

To go to the Drug Topics homepage, click here.